v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME        
Net sales $ 303,428 $ 294,146 $ 852,961 $ 835,382
Cost of sales 98,829 91,984 286,584 270,265
Gross margin 204,599 202,162 566,377 565,117
Operating expenses:        
Selling, general and administrative 111,840 99,238 332,839 291,624
Research and development 25,761 22,713 72,675 69,074
Total operating expenses 137,601 121,951 405,514 360,698
Operating income 66,998 80,211 160,863 204,419
Other income (expense) (5,914) (15) (16,835) 45,924
Earnings before income taxes 61,084 80,196 144,028 250,343
Income taxes 12,025 9,978 16,511 40,385
Net earnings, including noncontrolling interest 49,059 70,218 127,517 209,958
Net earnings attributable to noncontrolling interest 0 0 0 179
Net earnings attributable to Bio-Techne 49,059 70,218 127,517 209,779
Other comprehensive income (loss):        
Foreign currency translation income (loss) (11,981) 3,282 (5,558) (805)
Foreign currency translation reclassified to earnings with Eminence deconsolidation 0 0 0 119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 335 (1,708) (3,685) 2,302
Other comprehensive income (loss) (11,646) 1,574 (9,243) 1,616
Other comprehensive income (loss) attributable to noncontrolling interest 0 0 0 (33)
Other comprehensive income (loss) attributable to Bio-Techne (11,646) 1,574 (9,243) 1,649
Comprehensive income attributable to Bio-Techne $ 37,413 $ 71,792 $ 118,274 $ 211,428
Earnings per share attributable to Bio-Techne:        
Basic (in dollars per share) $ 0.31 $ 0.45 $ 0.81 $ 1.34
Diluted (in dollars per share) $ 0.31 $ 0.43 $ 0.79 $ 1.30
Weighted average common shares outstanding:        
Basic (in shares) 157,309 157,311 157,655 157,071
Diluted (in shares) 160,496 161,615 160,817 161,768

Source